GlassScriptPhysician profile
Alexis Mcafee
NPI 1538812318
$6,902.29
in general payments reported to CMS, 2019-2025
39 companies · $1,567 in 2025
The $1,567 reported for 2025 was more than what 91% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $1,109 · 2023: $2,316 · 2024: $1,910 · 2025: $1,567.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,793.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,793.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corcept Therapeutics | $947.61 | 2023-2025 | Korlym |
| Abbvie INC. | $591.33 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $586.76 | 2022-2025 | Airsupra, Breztri, Farxiga |
| Lilly USA, LLC | $521.67 | 2022-2025 | Mounjaro, Jardiance, Zepbound |
| Glaxosmithkline, LLC. | $504.14 | 2022-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Novo Nordisk INC | $454.52 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Bayer Healthcare Pharmaceuticals INC. | $444.15 | 2022-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $399.96 | 2022-2025 | Caplyta |
| Pfizer INC. | $295.25 | 2022-2025 | |
| Amgen INC. | $263.71 | 2023 | Repatha, Otezla |
| Biohaven Pharmaceutical Holding Company LTD. | $184.34 | 2022 | |
| Vanda Pharmaceuticals INC. | $182.69 | 2024-2025 | Fanapt, Hetlioz |
| Exact Sciences Corporation | $166.89 | 2023-2025 | Cologuard Collection Kit |
| Janssen Pharmaceuticals, INC | $139.57 | 2022-2025 | Spravato |
| Abiomed | $128.95 | 2022 |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $105.40 | 2023-2024 | Quviviq |
| Inspire Medical Systems, INC. | $97.40 | 2023-2024 | Inspire |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $86.36 | 2022-2025 | Xifaxan |
| Sanofi-Aventis U.S. LLC | $81.88 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $71.26 | 2022 | |
| Phathom Pharmaceuticals, INC. | $69.31 | 2024-2025 | Voquezna |
| Daiichi Sankyo INC. | $62.74 | 2023 | Injectafer |
| Alkermes, INC. | $62.54 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $62.49 | 2022-2025 | Jardiance, Synjardy, Trijardy Xr |
| Kowa Pharmaceuticals America, INC. | $51.15 | 2022-2024 | Zoryve |
| Lundbeck LLC | $43.16 | 2025 | Rexulti |
| Axsome Therapeutics, INC. | $40.80 | 2025 | Auvelity |
| Alk-Abello, INC | $32.97 | 2024 | Grastek, Ragwitek, Odactra |
| Hikma Pharmaceuticals USA | $30.97 | 2023 | Kloxxado, Mitigare, Ryaltris |
| Ethicon US, LLC | $22.10 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $21.82 | 2025 | Austedo Xr |
| Xeris Pharmaceuticals, INC. | $21.52 | 2025 | Recorlev |
| Astellas Pharma US INC | $21.08 | 2024 | Veozah |
| Philips North America LLC | $20.36 | 2024 | (Ck7) Extended Holter |
| Horizon Therapeutics Plc | $18.24 | 2023 | Krystexxa |
| Esperion Therapeutics, INC. | $18.20 | 2024 | Nexletol |
| Corium, LLC | $17.55 | 2025 | Azstarys |
| Dexcom, INC. | $15.82 | 2025 | Dexcom G6 Transmitter |
| Noven Therapeutics, LLC | $15.63 | 2024 | Xelstrym |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alexis Mcafee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.